Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

Therapies that produce deep and durable responses in patients with metastatic melanoma are needed. This phase II cohort from the international, single-arm PIVOT-02 study evaluated the CD122-preferential interleukin-2 pathway agonist bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in first-line meta...

Descripción completa

Detalles Bibliográficos
Autores principales: Diab, Adi, Tykodi, Scott S., Daniels, Gregory A., Maio, Michele, Curti, Brendan D., Lewis, Karl D., Jang, Sekwon, Kalinka, Ewa, Puzanov, Igor, Spira, Alexander I., Cho, Daniel C., Guan, Shanhong, Puente, Erika, Nguyen, Tuan, Hoch, Ute, Currie, Sue L., Lin, Wei, Tagliaferri, Mary A., Zalevsky, Jonathan, Sznol, Mario, Hurwitz, Michael E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425826/
https://www.ncbi.nlm.nih.gov/pubmed/34255535
http://dx.doi.org/10.1200/JCO.21.00675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425826/
https://www.ncbi.nlm.nih.gov/pubmed/34255535
http://dx.doi.org/10.1200/JCO.21.00675

Ejemplares similares